Fulcrum Therapeutics Income Statement (2019-2025) | FULC

Income Statement Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.75M2.00M1.85M4.22M4.79M4.38M4.93M5.06M2.59M1.88M1.18M0.69M0.29M0.88M0.76M0.87M80.00M
Operating items
Research & Development 14.48M12.78M15.64M16.14M16.33M17.38M17.08M18.91M17.83M25.02M15.37M18.57M16.71M17.85M18.24M19.00M19.77M17.26M14.64M11.71M12.99M14.30M
Selling, General & Administrative 5.06M5.15M5.31M5.87M5.50M6.68M8.63M9.71M10.76M11.10M9.71M10.13M11.52M10.32M9.96M9.86M10.06M10.25M8.42M7.72M6.83M7.56M
Restructuring Costs 0.47M-0.04M2.06M
Operating Expenses 19.55M17.92M20.95M22.01M21.83M24.06M25.70M28.62M28.59M36.12M25.54M28.66M28.23M28.17M28.20M28.86M29.83M27.51M25.13M19.43M19.82M21.86M
Operating Income -18.80M-15.92M-19.10M-17.79M-17.04M-19.68M-20.77M-23.56M-26.00M-34.23M-24.36M-27.97M-27.94M-27.29M-27.44M-27.99M-29.83M52.49M-25.13M-19.43M-19.82M-21.86M
EBIT -18.80M-15.92M-19.10M-17.79M-17.04M-19.68M-20.77M-23.56M-26.00M-34.23M-24.36M-27.97M-27.94M-27.29M-27.44M-27.99M-29.83M52.49M-25.13M-19.43M-19.82M-21.86M
Non-operating items
Interest & Investment Income 0.34M0.24M0.14M0.07M0.04M0.03M0.05M0.07M0.07M0.17M0.62M1.84M3.16M3.51M3.42M3.24M2.96M2.92M3.43M2.86M2.52M2.26M
Net income details
EBT -18.45M-15.69M-18.96M-17.72M-17.00M-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.30M-19.59M
Profit After Tax -18.45M-15.69M-18.96M-17.72M-17.00M-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.30M-19.59M
Income from Continuing Operations -18.45M-15.69M-18.96M-17.72M-17.00M-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.30M-19.59M
Consolidated Net Income -18.45M-15.69M-18.96M-17.72M-17.00M-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.30M-19.59M
Income towards Parent Company -18.45M-15.69M-18.96M-17.72M-17.00M-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.30M-19.59M
Net Income towards Common Stockholders -18.45M-15.69M-18.96M-17.72M-17.00M-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.30M-19.59M
Additional items
EPS (Basic) -0.81-0.66-0.70-0.63-0.54-0.60-0.57-0.58-0.64-0.83-0.51-0.47-0.41-0.38-0.39-0.40-0.430.89-0.35-267.29-0.28-0.31
EPS (Weighted Average and Diluted) -698.90-0.60-0.57-0.58-0.64-0.83-0.51-0.47-0.41-0.38-0.39-0.40-0.430.87-0.35-267.29-0.28-0.31
Shares Outstanding (Weighted Average) 0.00M0.00M0.02M0.01M0.02M0.02M0.03M0.03M31.51M0.03M0.04M0.04M0.04M0.04M0.05M0.04M0.06M61.79M61.82M0.06M61.98M62.20M62.41M0.06M62.48M62.54M62.60M
Shares Outstanding (Diluted Average) 0.03M0.03M0.04M0.04M0.04M0.04M0.05M0.04M0.06M61.79M61.82M0.06M61.98M63.68M63.69M0.06M62.48M62.54M62.60M
EBITDA -18.50M-15.55M-19.01M-17.75M-17.00M-19.65M-20.79M-23.79M-26.62M-34.05M-24.36M-27.97M-27.94M-27.29M-27.44M-27.99M-29.83M52.49M-20.95M-16.82M-19.82M-19.44M